Patents by Inventor Malcolm Maccoss

Malcolm Maccoss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120184574
    Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.
    Type: Application
    Filed: April 5, 2010
    Publication date: July 19, 2012
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Malcolm Maccoss, F. George Njoroge, Amin Nomeir, Guangming Chen, Song Xiao Huang, Ramesh Kakarla, Gary Mitchell Karp, William Joseph Lennox, Chunshi Li, Ronggang Liu, Yalei Liu, Christie Morrill, Steven D. Paget, Sean W. Smith, James Takasugi, Anthony A. Turpoff, Hongyu Ren, Nanjing Zhang, Xiaoyan Zhang, Jin Zhu
  • Publication number: 20120135999
    Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.
    Type: Application
    Filed: April 5, 2010
    Publication date: May 31, 2012
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Malcolm Maccoss, F. George Njoroge, Amin Nomeir, Guangming Chen, Gary Mitchell Karp, William Jospeh Lennox, Chunshi Li, Christie Morrill, Steven D. Paget, Hongyu Ren, Nanjing Zhang, Xiaoyan Zhang
  • Patent number: 8168637
    Abstract: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: May 1, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Edmondson, Dooseop Kim, Malcolm Maccoss, Emma R. Parmee, Ann E. Weber, Jinyou Xu
  • Publication number: 20110306593
    Abstract: In its many embodiments, the present invention provides a novel class of heterocyclic compounds of the formula: as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more disease associated with the central nervous system using such compounds or pharmaceutical compostions.
    Type: Application
    Filed: November 11, 2009
    Publication date: December 15, 2011
    Inventors: Zhaoning Zhu, William J. Greenlee, Hongmei Li, Monica L. Vicarel, Jun Qin, Pawan Kumar Dhondi, Xianhai Huang, Anandan Palani, Xiaoxiang Liu, Zhong-Yue Sun, Hubert B. Josien, Ruo Xu, David James Cole, Duane A. Burnett, Chad E. Bennett, Troy McCracken, Malcolm MacCoss
  • Publication number: 20110286969
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as wet! as methods of using them to treat disorders associated with the HCV protease An illustrative inventsve compound is shown below: Formula (I).
    Type: Application
    Filed: December 10, 2009
    Publication date: November 24, 2011
    Applicant: SCHERING CORPORATION
    Inventors: Malcolm MacCoss, F. George Njoroge, Frank Bennett, Srikanth Venkatraman, Joseph A. Kozlowski, Wensheng Yu, Paul E. McNamara, Pernilla R. Royster
  • Publication number: 20110190308
    Abstract: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: April 14, 2011
    Publication date: August 4, 2011
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Edmondson, Michael H. Fisher, Dooseop Kim, Malcolm Maccoss, Emma R. Parmee, Ann E. Weber, Jinyou Xu
  • Patent number: 7879815
    Abstract: The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: February 1, 2011
    Assignees: Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Malcolm MacCoss, David B. Olsen, Monica Donghi, Cristina Gardelli, Steven Harper, Malte Meppen, Frank Narjes, Barbara Pacini
  • Publication number: 20100234316
    Abstract: The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.
    Type: Application
    Filed: February 12, 2007
    Publication date: September 16, 2010
    Inventors: Malcolm MacCoss, David B. Olsen, Monica Donghi, Cristina Gardelli, Steven Harper, Malte Meppen, Frank Narjes, Barbara Pacini
  • Publication number: 20100130504
    Abstract: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: January 27, 2010
    Publication date: May 27, 2010
    Inventors: Scott D. Edmondson, Michael H. Fisher, Dooseop Kim, Malcolm Maccoss, Emma R. Parmee, Ann E. Weber, Jinyou Xu
  • Patent number: 7632821
    Abstract: The present invention provides ribonucleoside 2?,3?-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors or prodrugs of inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors or prodrugs of inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such ribonucleoside 2?,3?-cyclic acetals alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: December 15, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Gabor Butora, Kenneth Alan Koeplinger, Malcolm MacCoss, Daniel R. McMasters, David B. Olsen, Lihu Yang
  • Patent number: 7534767
    Abstract: The present invention provides C-purine nucleoside analogs and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such C-nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the C-nucleoside compounds of the present invention.
    Type: Grant
    Filed: June 10, 2005
    Date of Patent: May 19, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Gabor Butora, Malcolm MacCoss, Balkrishen Bhat, Anne B. Eldrup
  • Publication number: 20090118223
    Abstract: Novel 2?-C-methyl nucleoside 5?-monophosphate and 4?-C-methyl nucleoside 5?-monophosphate derivatives, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described.
    Type: Application
    Filed: August 14, 2006
    Publication date: May 7, 2009
    Inventors: Mark D. Erion, K. Raja Reddy, Malcolm MacCoss, David B. Olsen
  • Publication number: 20090099126
    Abstract: The present invention provides ribonucleoside 2?,3?-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as pre-cursors or prodrugs of inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors or prodrugs of inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such ribonucleoside 2?,3?-cyclic acetals alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection.
    Type: Application
    Filed: August 4, 2006
    Publication date: April 16, 2009
    Inventors: Gabor Butora, Kenneth Alan Koeplinger, Malcolm MacCoss, Daniel R. McMasters, David B. Olsen, Lihu Yang
  • Publication number: 20080280842
    Abstract: The present invention provides fluorinated pyrrolo[2,3,d]pyrimidine nucleoside compounds which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such fluorinated pyrrolo[2,3-d]pyrimidine nucleoside alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the fluorinated pyrrolo[2,3-d]pyrimidine nucleoside of the present invention.
    Type: Application
    Filed: October 17, 2005
    Publication date: November 13, 2008
    Applicant: MERCK & CO., INC.
    Inventors: Malcolm MacCoss, David B. Olsen, Joseph Leone, Philippe L. Durette
  • Publication number: 20080200376
    Abstract: The present invention relates to methods of treating and preventing obesity and obesity-related disorders in a subject comprising administering a neurokinin-1 antagonist and an anti-obesity agent, such as a melanocortin 4 receptor agonist, to said subject. The present invention further related to methods of treating or preventing sexual dysfunction, including male erectile dysfunction, in a subject comprising administering a neurokinin-1 antagonist and a sexual dysfunction therapeutic agent, such as a melanocortin 4 receptor agonist, to said subject. The present invention further provides for pharmaceutical compositions and medicaments useful in carrying out these methods.
    Type: Application
    Filed: October 25, 2005
    Publication date: August 21, 2008
    Inventors: Malcolm MacCoss, Duncan E. MacIntyre, Alison M. Strack
  • Publication number: 20080021047
    Abstract: The present invention provides C-purine nucleoside analogs and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such C-nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the C-nucleoside compounds of the present invention.
    Type: Application
    Filed: June 10, 2005
    Publication date: January 24, 2008
    Inventors: Gabor Butora, Malcolm MacCoss, Balkrishen Bhat, Anne Eldrup
  • Publication number: 20070265222
    Abstract: The present invention provides nucleoside aryl phosphoramidates which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.
    Type: Application
    Filed: June 20, 2005
    Publication date: November 15, 2007
    Inventors: Malcolm MacCoss, David Olsen
  • Publication number: 20070179114
    Abstract: Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:
    Type: Application
    Filed: November 6, 2006
    Publication date: August 2, 2007
    Applicants: Metabasis Therapeutics, Inc., Merck & Co., Inc.
    Inventors: Mark Erion, K. Reddy, Malcolm MacCoss, David Olsen
  • Publication number: 20070155731
    Abstract: Compounds of Formula I and Formula II (wherein A, E, j, k, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.
    Type: Application
    Filed: January 26, 2005
    Publication date: July 5, 2007
    Inventors: Gabor Butora, Deodialsingh Guiadeen, Shankaran Kothandaraman, Malcolm MacCoss, Sander Mills, Lihu Yang
  • Publication number: 20070135357
    Abstract: The instant invention provides novel cholesterol absorption inhibitors of Formula I and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.
    Type: Application
    Filed: October 27, 2004
    Publication date: June 14, 2007
    Inventors: Heather Sings, Feroze Ujjainwalla, Malcolm MacCoss, Robert Myers